Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$6.57
+0.10 (+1.55%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $126.5M · quality 84.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
54/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.8B
P/E
34.6x
↑EV/EBITDA
24.7x
↑ROE
13.2%
↑Gross Margin
75.4%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-7.0%
FCF CAGR
-10.6%
FCF margin
15.6%
FCF / Net income
1.33x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $817.0M · net income $95.7M · FCF $127.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $817.0M | $817.0M | $763.8M | $909.5M | $1.01B |
| Net Income | $95.7M | $95.7M | $36.4M | $58.8M | $107.4M |
| EBITDA | $133.9M | $133.9M | $75.1M | $87.9M | $146.1M |
| EPS | 0.17 | 0.17 | 0.06 | 0.10 | 0.19 |
| Gross Margin | 75.4% | 75.4% | 72.6% | 74.4% | 75.3% |
| Operating Margin | 11.8% | 11.8% | 5.6% | 5.8% | 11.1% |
| Net Margin | 11.7% | 11.7% | 4.8% | 6.5% | 10.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 2.10 | 2.10 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $127.7M | $127.7M | $87.7M | $126.5M | $178.5M |
| Returns | |||||
| ROE | 13.2% | 13.2% | 5.2% | 7.3% | 14.4% |
| Valuation | |||||
| P/E | 34.58 | 34.58 | 72.00 | 62.40 | 32.32 |
| EV/EBITDA | 24.68 | 24.68 | 30.32 | 37.16 | 21.85 |
| P/B | 5.11 | 5.11 | 3.76 | 4.55 | 4.65 |
| Growth & Yield | |||||
| Revenue Growth | 7.0% | 7.0% | -16.0% | -10.4% | — |
| EPS Growth | 183.3% | 183.3% | -40.0% | -47.4% | — |
| Dividend Yield | 4.0% | 4.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
50.8%
EPS terminal req.
$0.58
Spread vs growth
132.5%
5Y implied EPS CAGR
32.9%
EPS terminal req.
$0.71
Spread vs growth
150.4%
10Y implied EPS CAGR
20.9%
EPS terminal req.
$1.14
Spread vs growth
162.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+25.3%
Start / end P/E
90.3x → 38.6x
EPS bridge
0.06 → 0.17
Residual
-104.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.